February 19, 2025
Aptose Announces Reverse Share Split
SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:…
Pharmaceuticals, Biotechnology and Life Sciences
SAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:…
TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that…
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total…
Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from…
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in…
REDWOOD CITY, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient…
PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that…
CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused…
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a…
JENA, Germany, Feb. 18, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics…